Abstract:Mateo Sanchis-Borja, 1 Florian Guisier, 2 Aurélie Swalduz, 3 Hubert Curcio, 4 Victor Basse, 5 Christophe Maritaz, 6 Christos Chouaid, 1 Jean-Bernard Auliac 1 1 Pulmonology Department, Créteil Intercommunal Hospital, Créteil, France; 2 Normandie Univ, UNIROUEN, LITIS Laboratory QuantIF team EA4108, CHU Rouen, Department of Pneumology and Inserm CIC-CRB 1404, Rouen, France; 3 Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France; 4 Department of Medical Oncology, Centre François Baclesse, Caen, France; 5 Department of Oncology CHU Morvan, Brest, France; 6 Medical Affairs Department, Oncology, Boehringer Ingelheim France, Paris, France Correspondence: Jean-Bernard Auliac, Pulmonology Department, Créteil Intercommunal Hospital, Créteil, France, Email Purpose: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, is an effective first-line therapy for patients with common EGFR mutation-positive non-small cell lung cancer (NSCLC). However, almost all patients become resistant to treatment. In some patients, emergence of tertiary EGFR mutations is implicated as a resistance mechanism. This study describes patients with NSCLC who acquired the rare EGFR mutations, L718Q or G724S, following EGFR TKI treatment. Patients and Methods: This was a retrospective, observational study undertaken in France from Feb–Nov 2021, in patients with EGFR mutation-positive NSCLC with an acquired L718Q or G724S mutation. Primary objectives were description of tumor characteristics, progression, and progression under treatment. Results: Nine eligible patients were identified. Acquired resistance to initial EGFR TKI treatment was associated with T790M emergence in six patients, who then received osimertinib monotherapy. Overall, eight patients received osimertinib monotherapy treatment at some point (average treatment duration: 18.3 months). Following the emergence of L718Q or G724S, patients received chemotherapy (n = 4; two of whom subsequently received afatinib), nivolumab (n = 2), afatinib (n = 2), or immunochemotherapy (n = 1). In the four patients who received afatinib after identification of L718Q or G724S, 2 achieved a partial response, one had stable disease and one had progressive disease. Treatment duration was 1.6– 31.7 months. In patients with controlled disease (n = 3), progression-free survival was 6.1– 31.7 months. Two of these patients had previously received osimertinib. Conclusion: Currently, there is no consensus regarding the treatment of EGFR mutation-positive NSCLC following emergence of the osimertinib resistance mutations, L718Q or G724S. Afatinib appears to be a promising treatment option in this setting. Keywords: osimertinib, afatinib, real-world evidence, tertiary EGFR mutations Activating mutations in the epidermal growth factor receptor ( EGFR) gene are present in approximately 10–15% of Caucasian patients with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology (11% in France), 1 rising to about 50% in Asian patients. 2 First-line standard of care for these patients comprises monotherapy with an EGFR tyrosine kinase inhibitor (TKI). Three generations of EGFR TKI are available which have different mechanisms of action; the first-generation reversible EGFR TKIs (erlotinib and gefitinib), the second-generation ErbB family blockers (afatinib and dacomitinib), and the third-generation irreversible EGFR TKI, osimertinib. 2 Head-to-head prospective trials have demonstrated the superiority of second- and third-generation TKIs over first-generation EGFR TKIs. 3–5 Based on the Phase III FLAURA trial, 4,6 which demonstrated overall survival (OS) benefit with osimertinib versus erlotinib/gefitinib and favorable tolerability, osimertinib is often used as treatment of choice for EGFR mutation-positive NSCLC. However, disease progression is ultimately inevitable. 7 Most randomized clinical trials of EGFR TKIs have been restricted to patients with so called "common" EGFR mutations, comprising deletions of exon 19 (Del19) and L858R in exon 21; these two mutations represent a large majority of the EGFR mutations detected. 8 Consequently, few prospective data are available to inform treatment decisions for the estimated 7–23% of EGFR mutation-positive NSCLC tumors that harbor uncommon EGFR mutations. 9 Uncommon EGFR mutations are highly heterogeneous. In silico and in vitro observations indicate that the sensitivity of -Abstract Truncated-

Newly Emergent Acquired EGFR Exon 18 G724S Mutation after Resistance of a T790M Specific EGFR Inhibitor Osimertinib in Non-Small-cell Lung Cancer: a Case Report.

Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report

Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients

Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer

[Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer]

A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report

Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report

Potential Resistance Mechanisms Using Next Generation Sequencing from Chinese EGFR T790M+ Non-Small Cell Lung Cancer Patients with Primary Resistance to Osimertinib: A Multicenter Study

An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report

Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France

A Case Report of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors with T790M Mutation and Epithelial-to-mesenchymal Transition

Gene Mutational Profiling Of Chinese Egfr-T790m Mutation Nsclc Patients Required Resistance To Osimertinib By Next Generation Sequencing

Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC

Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report